Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial ishikawa cells

Molecular Pharmacology

Volumn 68, Issue 6, 2005, Pages 1852-1862

  Rocha, Walter ^a,b   Sanchez, Rocio ^a   Deschênes, Julie ^a,b   Auger, Anick ^a   Hébert, Elise ^a,b   White, John H ^b,c   Mader, Sylvie ^a,b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; ARTICLE; CARCINOMA CELL; DRUG EFFECT; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; GENE CONTROL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HISTONES; HUMANS; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 27844569881     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.014514     Document Type: Article

References (40)

1. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, and Vigushin DM (2004) Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10:8094-8104.
2. Barsalou A, Dayan G, Anghel SI, Alaoui-Jamali M, Van de Velde P, and Mader S (2002) Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells. Mol Cell Endocrinol 190:65-73.
3. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, and Mader S (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18:1411-1427.
4. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N, et al. (2003) Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 11:139-150.
5. Fu M, Wang C, Zhang X, and Pestell RG (2004) Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 68:1199-1208.
6. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, and Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
7. Graziani G, Tentori L, Portarena I, Vergati M, and Navarra P (2003) Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinology 144:2822-2828.
8. Hsu SC and DeFranco DB (1995) Selectivity of cell cycle regulation of glucocorticoid receptor function. J Biol Chem 270:3359-3364.
9. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, and Lee JS (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23:1724-1736.
10. Jenuwein T and Allis CD (2001) Translating the histone code. Science (Wash DC) 293:1074-1080.
11. Kawai H, Li H, Avraham S, Jiang S, and Avraham HK (2003) Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107:353-358.
12. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, and Davidson NE (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81:177-186.
13. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588.
14. King KL and Cidlowski JA (1998) Cell cycle regulation and apoptosis. Annu Rev Physiol 60:601-617.
15. Kinyamu HK and Archer TK (2004) Modifying chromatin to permit steroid hormone receptor-dependent transcription. Biochim Biophys Acta 1677:30-45.
16. Kos M, Reid G, Denger S, and Gannon F (2001) Minireview: genomic organization of the human ERalpha gene promoter region. Mol Endocrinol 15:2057-2063.
17. Lipka C, Mankertz J, Fromm M, Lubbert H, Buhler H, Kuhn W, Ragosch V, and Hundertmark S (2004) Impairment of the antiproliferative effect of glucocortico-steroids by 11beta-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast-cancer cells. Horm Metab Res 36:437-444.
18. Littlefield BA and Cidlowski JA (1984) Increased steroid responsiveness during sodium butyrate-induced "differentiation" of HeLa S3 cells. Endocrinology 114:566-575.
19. Mader S and White JH (1993) A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells. Proc Natl Acad Sci USA 90:5603-5607.
20. Mao C and Shapiro DJ (2000) A histone deacetylase inhibitor potentiates estrogen receptor activation of a stably integrated vitellogenin promoter in HepG2 cells. Endocrinology 141:2361-2369.
21. Margueron R, Duong V, Bonnet S, Escande A, Vignon F, Balaguer P, and Cavailles V (2004a) Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol 32:583-594.
22. Margueron R, Duong V, Castet A, and Cavailles V (2004b) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68:1239-1246.
23. McLaughlin F, Finn P, and La Thangue NB (2003) The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov Today 8:793-802.
24. McLaughlin F and La Thangue NB (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68:1139-1144.
25. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, and Gannon F (2003) Estrogen receptor-alpha directs ordered, cyclical and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751-763.
26. Mulholland NM, Soeth E, and Smith CL (2003) Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. Oncogene 22:4807-4818.
27. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, and Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497.
28. Nagao M, Oyanagi K, Tsuchiyama A, Aoyama T, and Nakao T (1987) Studies on the expression of liver-specific functions of human fetal hepatocytes in primary culture. Tohoku J Exp Med 152:23-29.
29. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, and Johnstone RW (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:3697-3702.
30. Plesko MM, Hargrove JL, Granner DK, and Chalkley R (1983) Inhibition by sodium butyrate of enzyme induction by glucocorticoids and dibutyryl cyclic AMP. A role for the rapid form of histone acetylation. J Biol Chem 258:13738-13744.
31. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, and Gannon F (2005) Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24:4894-4907.
32. Rosenfeld MG and Glass CK (2001) Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865-36868.
33. Ruh MF, Tian S, Cox LK, and Ruh TS (1999) The effects of histone acetylation on estrogen responsiveness in MCF-7 cells. Endocrine 11:157-164.
34. Sanchez R, Nguyen D, Rocha W, White JH, and Mader S (2002) Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24:244-254.
35. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, and Ford CD (2002) Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb and Id proteins. Mol Cancer Ther 1:1181-1190.
36. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, and Koeffler HP (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141-1149.
37. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, and Gronemeyer H (1998) The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO (Eur Mol Biol Organ) J 17:507-519.
38. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, et al. (2001) Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276:18375-18383.
39. White JH, Fernandes I, Mader S, and Yang XJ (2004) Corepressor recruitment by agonist-bound nuclear receptors. Vitam Horm 68:123-143.
40. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, and Davidson NE (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61:7025-7029.